Starcoin Group Explores NASDAQ De-SPAC Deal With Newbridge Acquisition

Innovative Pharmaceutical Biotech ( (HK:0399) ) has provided an announcement.

Starcoin Group Limited has signed a memorandum of understanding with Newbridge Acquisition Limited, a NASDAQ-listed special purpose acquisition company, to explore a potential de-SPAC transaction involving the group and its assets or businesses. The non-binding MOU, dated 27 February 2026, sets a 180-day window for due diligence and negotiation of definitive agreements, after which it will lapse unless extended by mutual consent.

Management views the prospective de-SPAC deal as a major strategic milestone that could give the group direct access to U.S. capital markets and broaden its fundraising options to support business development and expansion. The board also believes a successful transaction would endorse the group’s business model and growth strategy, help unlock intrinsic value for shareholders, and potentially strengthen its competitive position, while cautioning investors that the deal may or may not proceed.

The most recent analyst rating on (HK:0399) stock is a Hold with a HK$0.18 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda. The group operates businesses whose growth strategy and market potential it is seeking to validate and expand, with an eye on accessing international capital markets, particularly in the United States.

Average Trading Volume: 26,957,435

Technical Sentiment Signal: Sell

Current Market Cap: HK$387.8M

Learn more about 0399 stock on TipRanks’ Stock Analysis page.